Analysts Expect Menlo Therapeutics (MNLO) Will Announce Quarterly Sales of $560,000.00

Brokerages expect that Menlo Therapeutics (NASDAQ:MNLO) will post sales of $560,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Menlo Therapeutics’ earnings, with estimates ranging from $500,000.00 to $610,000.00. The business is expected to issue its next quarterly earnings results on Wednesday, June 27th.

On average, analysts expect that Menlo Therapeutics will report full-year sales of $3.22 million for the current year, with estimates ranging from $2.00 million to $4.44 million. For the next financial year, analysts forecast that the business will post sales of $2.72 million per share, with estimates ranging from $1.00 million to $4.44 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Menlo Therapeutics.

How to Become a New Pot Stock Millionaire

Menlo Therapeutics (NASDAQ:MNLO) last issued its quarterly earnings results on Wednesday, March 28th. The company reported ($1.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($1.11). The business had revenue of $2.78 million for the quarter.

MNLO has been the subject of several recent research reports. Jefferies Group initiated coverage on shares of Menlo Therapeutics in a research report on Tuesday, February 20th. They issued a “buy” rating and a $41.00 price target for the company. Guggenheim initiated coverage on shares of Menlo Therapeutics in a research report on Monday, February 19th. They issued a “buy” rating and a $52.00 price target for the company. JMP Securities initiated coverage on shares of Menlo Therapeutics in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $44.00 price target for the company. Finally, Piper Jaffray initiated coverage on shares of Menlo Therapeutics in a research report on Tuesday, February 20th. They issued an “overweight” rating and a $48.00 price target for the company.

In other news, major shareholder Vivo Capital Surplus Fund Viii acquired 294,118 shares of Menlo Therapeutics stock in a transaction dated Thursday, January 25th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $5,000,006.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

MNLO stock traded up $0.02 during midday trading on Friday, hitting $9.53. The company’s stock had a trading volume of 47,581 shares, compared to its average volume of 237,182. Menlo Therapeutics has a 52-week low of $7.94 and a 52-week high of $39.86.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Menlo Therapeutics (MNLO) Will Announce Quarterly Sales of $560,000.00” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/04/17/analysts-expect-menlo-therapeutics-mnlo-will-announce-quarterly-sales-of-560000-00.html.

About Menlo Therapeutics

Menlo Therapeutics Inc, a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply